TrialClinical pharmacology and therapeutics2018

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.

Johann Bartko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.